NCT01151046 2016-05-12
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
Merrimack Pharmaceuticals
Phase 2 Completed